Home
HelpTest Code LAB4410 NAbFeron (IFNB-1) Neutralizing Antibody Test
Additional Codes
| Test Name in EPIC | EPIC Test Code | Mnemonic | Mayo Test ID |
|---|---|---|---|
| INTERFERON NEUTRAL AB | LAB4410 | NAB | FINA |
Reporting Name
NAbFeron (IFN-B) AntibodyUseful For
Detection of antibodies to interferon-B-1
Method Name
Viral cytopathic effect assay
Performing Laboratory
Athena DiagnosticsSpecimen Type
SerumSpecimen Required
Specimen Type: Serum
Container/Tube: Red or SST
Specimen Volume: 2 mL
Collection Instructions: Draw blood in a plain red-top tube(s), serum gel tube is acceptable. Spin down and send 2 mL of serum refrigerate in a plastic vial.
Note: Sample needs to be collected either before treatment with interferon or more than 24 hours following the most recent dose. Patient should not be on steroid therapy for at least two weeks prior to testing.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 28 days | |
| Frozen | 180 days | ||
| Ambient | 72 hours |
Reject Due To
| Hemolysis | NA |
| Lipemia | NA |
| Icterus | NA |
| Other | NA |
Reference Values
Final report has been sent to the referring laboratory.
Day(s) Performed
Monday through Friday
CPT Code Information
86382
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| FINA | NAbFeron (IFN-B) Antibody | Not Provided |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| Z0083 | NAbFeron (IFN-B) Antibody | Not Provided |
Test Classification
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. .Report Available
14 to 25 daysCautions
The present of neutralizing antibodies to interferon beta, especially in persistently high titers, may be associated with reduction in the clinical effectiveness of interferon beta therapy (1). Although the measurement of Nabs can add to the clinical and imaging information used to assess the efficacy of interferon beta therapy, these results should be interpreted in the context of clinical presentation and medical history (2, 3).
Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data.